Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$0.03 – $0.24
25% from low
Exchange
OTC Link
OS
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.9M | $4.5M | $5.8M | $19.0M | $11.6M | $10.5M | $11.1M | $12.5M |
| Cost of revenue | $1.1M | $2.4M | $3.3M | $18.3M | $7.2M | $14.7M | $4.0M | $4.6M |
| Gross profit | $837.8K | $2.0M | $2.5M | $638.1K | $4.5M | −$4.3M | $7.1M | $7.9M |
| Gross margin | 43.7% | 45.5% | 43.4% | 3.4% | 38.3% | -40.6% | 63.8% | 63.2% |
| R&D | $184.8K | $573.5K | $1.9M | $1.2M | $1.3M | $246.0K | $69.0K | $106.0K |
| Operating income | −$1.3M | −$2.9M | −$10.7M | −$11.1M | −$23.9M | −$6.6M | −$7.1M | −$7.8M |
| EBITDA | −$1.2M | −$2.4M | −$8.2M | −$10.5M | −$40.2M | −$2.8M | −$5.4M | −$4.6M |
| Net income | −$1.3M | −$4.6M | −$9.3M | −$15.1M | −$45.7M | −$8.9M | −$8.6M | −$7.2M |
| Net margin | -66.0% | -102.6% | -160.2% | -79.7% | -393.2% | -84.3% | -77.2% | -57.5% |
| EPS (diluted) | -0.01 | -0.03 | -0.05 | -0.09 | -0.30 | -0.04 | -0.02 | -0.01 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $14M | $-0.00 | $-0.00–$-0.00 | 1 |
| 2027 | $25M | $-0.00 | $-0.00–$-0.00 | 1 |
| 2028 | $38M | $0.02 | $0.02–$0.02 | 1 |
Forward consensus · source: Financial Modeling Prep
LUMOS DIAGNOSTICS HLDGS
No one on the platform currently holds LDXHF.
No tracked institution reports a position in LDXHF as of their last filing.
No one on the platform has traded LDXHF yet.
| +0.00% |
| $212M |
| — |
| SHIEFShield Therapeutics plc | $0.08 | +0.00% | $86M | — |
| SNZZFSenzime AB (publ) | $0.48 | +0.00% | $75M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 0.6× sales vs its 3.4× historical median P/S.
Fair value ≈ $0.44 · price $0.08 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.